1) receptor activator of nuclear factor-κB
核因子κB受体活化剂
1.
Osteoprotegerin ligand exerts its biologic effects such as stimulating osteoclasts differentiation, fusion and activating the mature ones through binding to receptor activator of nuclear factor-κB.
核因子κB受体活化剂 ,是肿瘤坏死因子受体超家族成员 ,是骨保护素配体在破骨细胞上的受体 ,骨保护素配体通过与核因子κB受体活化剂结合 ,将细胞分化等信号传入破骨细胞前体内 ,促进其分化、融合 ,并促进成熟破骨细胞的激活过程。
2.
Objective The purpose of this experiment is to observe the expression of receptor activator of nuclear factor-κB(RANK) and study it s function during the stages of the replacement of dog s primary and permanent teeth.
目的 观察犬乳恒牙替换中核因子κB受体活化剂 (receptoractivatorofnuclearfactor -κB ,RANK )的表达 ,探讨其在此过程中所起的作用。
2) receptor activator of nuclear factor-κB
核因子κB受体活化因子
1.
Recombinant soluble receptor activator of nuclear factor-κB inhibits parathyroid hormone-induced osteoclastogenesis in vitro;
重组可溶性核因子κB受体活化因子体外抑制甲状旁腺激素诱导的破骨细胞生成
3) receptor activator nuclear factor-κB
核因子-κB受体活化因子
1.
Osteoprotegerin and receptor activator nuclear factor-κB ligand and receptor activator nuclear factor-κB system and tooth eruption;
骨保护蛋白-核因子-κB受体活化因子配体-核因子-κB受体活化因子系统与牙萌出
4) receptor activator of the nuclear factor-kappa B ligand
核因子κB受体活化剂配体RANKL
1.
Objective:To observe the expression of the receptor activator of the nuclear factor-kappa B ligand(RANKL) mRNA at the occlusal surface of tooth germ in rat mandibular first molar and the differentiation of osteoclast.
目的:探讨核因子κB受体活化剂配体RANKL在大鼠下颌第一磨牙牙胚冠方组织中mRNA的表达及破骨细胞的分化情况。
6) RANKL
核因子-κB受体活化因子配体
1.
Objective To study the effects of tumor necrosis factor-alpha(TNF-α)on the gene expression of receptor activator of nuclear factor-κB ligand(RANKL) and osteoprotegerin(OPG) in human periodontal ligament fibroblasts(HPDLFs).
目的探讨肿瘤坏死因子-α(TNF-α)对人牙周膜成纤维细胞(HPDLFs)的核因子-κB受体活化因子配体(RANKL)及其饵受体骨保护素(OPG)mRNA表达的影响,了解TNF-α在破骨细胞性骨吸收调节中的作用机制。
2.
The objective of this study was to explore the effect of sodium fluoride on the expression of RANKL to OPG mRNA in mouse osteoblasts.
为探讨氟化钠对小鼠成骨细胞中核因子-κB受体活化因子配体(RANKL)和骨保护素(OPG)mRNA表达比率的影响,选取新生小鼠颅盖骨,用胰蛋白酶-胶原酶消化法分离培养成骨细胞。
3.
In recent years,the OPG/RANKL/RANK system has made a great breakthrough in bone research field,the results showed that many hormones and cytokines can directly or indirectly regulate the expression of osteoprotegerin(OPG) and receptor activator of NF-κB ligand(RANKL),and control the rate among OPG/RANKL/RANK,thus it could play a role in prevent or promote osteoporosis development.
OPG/RANKL/RANK系统是近年来骨科研究领域中的重大突破,研究发现许多激素、细胞因子等均通过直接或间接的调节骨保护素(osteoprotegerin,OPG),核因子-κB受体活化因子配体(receptor activator ofNF-κB ligand,RANKL)的表达,调控OPG、RANKL和核因子-κB受体活化因子(recep-tor activator of NF-κB,RANK)之间的比例,从而介导破骨细胞的分化和功能而达到抗骨质疏松或致骨质疏松的作用。
补充资料:三丁氧基(2,4-戊二酮根合-κO,κO')-锆
CAS:85626-36-4
中文名称:三丁氧基(2,4-戊二酮根合-κO,κO')-锆
英文名称:tributoxy(2, 4-pentanedionato-.kappa.O, .kappa.O')-Zirconium; Zirconium,tributoxy(2,4-pentanedionato-.kappa.O,.kappa.O')-
中文名称:三丁氧基(2,4-戊二酮根合-κO,κO')-锆
英文名称:tributoxy(2, 4-pentanedionato-.kappa.O, .kappa.O')-Zirconium; Zirconium,tributoxy(2,4-pentanedionato-.kappa.O,.kappa.O')-
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条